Personalized Medicine and Biomarker Discovery to Targeted Therapies in Breast Cancer : Focus on CDK4/6 Inhibitors
L’avènement du séquençage haut débit a mis en lumière l’hétérogénéité des cancers du sein qui peuvent être groupés en fonction d’altérations moléculaires spécifiques qui sont pour certaines à la base de thérapies ciblées dans le cadre de la médecine personnalisée. Néanmoins de nombreuses complicatio...
Main Author: | Arnedos Ballester, Monica |
---|---|
Other Authors: | Paris Saclay |
Language: | fr |
Published: |
2019
|
Subjects: | |
Online Access: | http://www.theses.fr/2019SACLS181 |
Similar Items
-
Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01) -
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01) -
CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
by: Wei Liu, et al.
Published: (2021-02-01) -
CDK4: A Novel Therapeutic Target for Extramammary Paget’s Disease
by: Hiroki Hashimoto, et al.
Published: (2021-07-01) -
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)